Strategic Acquisition Quince recently acquired OrphAI Therapeutics to build a rare pulmonary disease pipeline, signaling an expanded product portfolio and potential cross-selling opportunities with their AIDE technology and future delivery platforms.

AIDE Platform Value The Autologous Intracellular Drug Encapsulation platform enables chronic administration of toxic or poorly distributed drugs, creating opportunities to partner on co development or licensing of_new formulations for additional rare diseases beyond A-T.

Phase 3 Lead EryDex is in pivotal Phase 3 with FDA SPA and Fast Track designation, offering a clear near term path to NDA and potential collaboration on companion diagnostics, manufacturing scale partnerships, or regional licensing as topline data nears.

Global Trials International multicenter NEAT study for EryDex presents opportunities to engage CROs, site networks, and payer conversations across regions, enabling joint ventures or regional market access strategies.

Financial Readiness With substantial funding and a mid sized revenue range, Quince is positioned for partnering discussions, strategic collaborations, and milestone-driven deals with larger biopharma seeking niche delivery platforms and rare disease assets.